Clinical trial
Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's…
NCT00026182 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00026182 |
|---|---|
| Title | Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma |
| Official title | Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma |
| Intervention type | Biological, Other, Procedure |
| Interventions | rituximab, recombinant interleukin-12, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment |
| Enrollment | 99 |
| Start date | Oct 1, 2001 |
| Primary completion | Feb 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: